Atrys Health, S.A. (A2T.F)
Frankfurt · EUR · Healthcare · Biotechnology
€2.48 (-2.36%) as of
Key statistics
- Market cap
- 188.25M
- EPS (TTM)
- -0.6500
- Dividend yield
- 0.00%
- 52-week range
- 2.0550 – 3.2300
- Beta
- 0.52
- Revenue (TTM)
- 147.68M
- Profit margin
- -65.95%
- Volume
- 3.08k
About Atrys Health, S.A.
Atrys Health, S.A., together with its subsidiaries, provides diagnostic services and medical treatments in Spain, Portugal, and Latin America. It operates through three segments: Diagnosis, Oncology, and Preventive Medicine. The company offers integrated diagnostics services comprising structural and molecular pathology, genetics, and nuclear medicine diagnosis; telediagnosis activities in the fields of radiology and cardiology; oncology treatment services, such as chemotherapy, immunotherapy, radiotherapy, and brachytherapy; second opinion and genetic counselling; and diagnostic reports and genetic tests. It also provides telemedicine services, such as teleradiology, telecardiology, teleoncology, teledermatology, teleophthalmology, and teleconsultations; prevention plans for companies, which includes training plans on occupational risk prevention; Smart Data, a technological database for healthcare; and research and development services. The company was formerly known as Althia Health, S.L. and changed its name to Atrys Health, S.A. in May 2016. Atrys Health, S.A. was incorporated in 2007 and is headquartered in Madrid, Spain.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Madrid, Spain
- Employees
- 763
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.